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Abstract The structure of the ollgomerization domain of the 
p53 tumor suppressor protein was determined in the trigonal 
crystal form, using a refined NMR structure as a model. A 
synthetic peptide comprising residues 319-360 of human p53 
crystallized in the space group P3121. There is one biologically 
relevant tetrameric domain in the crystallographic asymmetric 
unit. The structure was relined jointly with NMR data, only the 
third such case (the previous examples being IL-lp (Shaanan, B., 
Gronenborn, A.M., Cohen, G.H., Gilliland, G.L., Veerapandian, 
B., Davies, D.R. and Clore, G.M. (1992) Science 257, 961-964 
[1]) and BPTI (Schiffer, C., Huber, R., Wuthrich, K. and Van 
Gunsteren, W.F. (1994) J. Mol. Biol. 241, 588-599 [2])), to 2.5 
A resolution with an R factor of 0.207. The distribution of tumor- 
derived mutations in the oligomerizatlon region together with 
structural and biological data suggest a strategy for the design of 
antitumor therapeutics. 
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1. Introduction 
The DNA-binding phosphoprotein, ~53 functions as a tu- 
mor suppressor in human cells by activating transcription of 
genes that mediate cell cycle arrest and DNA damage repair 
[3-51 and by inducing apoptosis in response to the activation 
of oncogenes [6,7]. In this way, p53 controls cell proliferation, 
and indeed 50% of human cancers have been shown to be 
associated with mutations in ~53. Wild-type (w-t) ~53 is active 
as tetramer and its biological function depends on its ability 
to self-associate, as well as on interactions with other cellular 
and viral proteins. The ~53 protein comprises a transactivat- 
ing region, a DNA-binding region, and an oligomerization 
region [&lo]. The C-terminal region also shows non-specific 
binding to single-stranded DNA and RNA and enhances spe- 
cific DNA binding by the whole molecule [l 11. Although the 
oligomerization is necessary for tumor suppressor activity, the 
tetramerization domain is responsible for the negative domi- 
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nant mechanism since ~53 molecules with mutations in the 
DNA-binding region can form heterotetramers with w-t ~53 
via the oligomerization domain, thus sequestering the w-t pro- 
tein into non-functional tetramers [12]. For these reasons, the 
structural mechanism of oligomerization is of great interest. 
The structure of the oligomerization domain has been de- 
termined by NMR [13-161 and by X-ray crystallography [17] 
methods using slightly different peptide segments. Discrepan- 
cies between the crystal structure [17] and the initial NMR 
structures [13,14] of this protein point out the technical diffi- 
culties involved in solving the solution structure of this sym- 
metric homotetramer [15]. Two NMR structures [14,16] show 
significant (up to 20”) differences in interhelical angles. 
Although the refined NMR structure [15,16] agrees remark- 
ably well with the crystal structure [17], the latter is a tetramer 
with a perfect crystallographic 222 symmetry. 
Here we describe the crystal structure of the ~53 tetramer- 
ization domain, in a trigonal crystal form, with the entire 
tetramer in the crystallographic asymmetric unit. Unambigu- 
ous solution was obtained using NMR tetramer [16] as a 
probe for molecular replacement, and the final refinement 
was performed jointly against experimental data from crystal 
and solution studies. Thus, the results obtained confirm that 
the structure of ~53 tetramerization domain is unique and 
stable, independently of environmental features. On the other 
hand, observed differences in the conformations of several 
residues located on the surface of the tetramer allow a re- 
evaluation of their importance to the stability of the tetramer. 
2. Materials and methods 
The peptide corresponding to residues 319-360 of human ~53 was 
obtained by chemical synthesis. Crystals grew as rhombohedral plates 
at room temperature, using the hanging-drop or sitting-drop vapor 
diffusion method and 5565% saturated ammonium phosphate solu- 
tions. Crystals_belonged to the trigonal space group P3i21, a = 51.0 A 
and c = 113.3 A, with one tetramer in the asymmetric unit. Digraction 
extended up to 2.0 A, but the intensity fell of rapidly below 3 A. Data 
were collected from a single crystal to 2.1 A nominal resolution, using 
the RAXIS IIC imaging plate and were processed with the Molecular 
Structure Corp. software. A total of 16849 accepted observations 
(I? 1.0 or) were reduced to 7387 unique reflections out of 10975 
possible to 2.1 A resolution;Othe Rsymm was 0.081. The completeness 
of the data was 82% to 2.7 A resolution (Rsymm = 0.071) and 71% tp 
2.5 A (&mm = 0.076). In each 0.1 A shell between the 2.6 and 2.2 A 
resolution range the data were only 50% complete and the mean I/q 
was 1.7. 
The structure was solved by molecular replacement [18], using the 
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refined mean coordinates of the NMR tetramer [16] as the probe. All 
atoms from residues 325-355 were used in the model. Rotation and 
translation searches, as well as the subsequent refinement cycles, were 
performed using the X-PLOR (version 3.1) package [19]. As expected, 
the rotation search gave four peaks related by non-crystallographic 
symmetry (NCS). At lo-4 A resolution, these peaks were higher than 
the fifth peak by one standard deviation. A translation search in 
P3121 g?ve an unambiguous peak with an R factor of 0.489 in the 
10-3.5 A resolution range, whereas a translation search in the enan- 
tiomeric space group P3221 did not result in any significant peak. 
For the crystallographic refinement 8% of reflections were removed 
from the 8-2.7 A resolution range for the Rfree calculations [20]. Rigid 
body refinement of the four monomers decreased the R factor to 0.445 
(Rbee 0.467). An inspection of the crystal packing in the original 
molecular replacement solution revealed several close contacts involv- 
ing side chains of symmetry-related molecules. Initially, the side 
chains of Arg-335 and Arg-342 were replaced with Ala in each sub- 
unit. Even then the refinement with strictly constrained NCS resulted 
in either high R values or the loss of secondary structure elements. 
Therefore, tightly restrained NCS was applied instead. After- the first 
simulated annealing and positional refinement in the 8-2.7 A resolu- 
tion range (using effective force constants for NCS restraints of 400 
and 200 kcal mol-’ Ae2 for the main chain and side chains, respec- 
tively), the R factor decreased to 0.355 (Rh,, 0.413). All missing Arg 
side-chains were modeled back and the refinement was continued with 
NCS restraints of 250 kcal mol-’ A-’ for all residues, except those 
involved in the crystal contacts. After extensive rebuilding with pro- 
gram FRODO [21] followed by simulated annealing and positional 
refinement, the structure was refined to an R factor of 0.239 (Rkee 
0.317). 
weights for NMR restraints and the crystallographic pseudo-energy 
term (wa) were chosen by trial and error. After each round of manual 
intervention and refinement, the quality of the model was tested by 
the program PROCHECK [25] and the refinement parameters were 
adjusted until satisfactory geometry and agreement with electron den- 
sity were achieved. Residues 319-324 and 356360, corresponding to 
the N- and C-termini of the peptide used for crystallization, could not 
be traced in the electron density for all monomers. These residues 
were highly mobile in solution structure [16], and only segments 
325-365 were traced in the tetragonal crystal fop [17]. The peaks 
in (F,-F,) difference Fourier maps within 3.6 A from the protein 
atoms were interpreted as water molecules. Only those involved in 
hydrogen-bond interactions and with B values smaller then 60 A2 
after refinement were retained. Refinement of individual-temperature 
factors (Bi,,), with NCS restraints set to 25 kcal mol-’ A-‘, resulted 
in an R factor of 0.207 with good geometry and an average Biso of 
29.5 AZ for protein atoms. 
Simulated annealing under the same conditions with 8% of reflec- 
tions excluded from the refinement resulted in a model of unchanged 
quality with an R factor of 0.205 (R free 0.296). When NMR restraints 
were removed from the refinement, while w, was unchanged, the val- 
ues were 0.200 and 0.301 for R factor and Rb,, respectively, but the 
quality of the model was worse (see Table 1). The high content of 
disordered residues in the crystal probably accounts for the poor 
diffraction by the crystal and the high Rfree/R factor ratio of the 
refined models. 
3. Results and discussion 
This model was then subjected to joint X-ray and NMR refinement 
[l] against all unique reflections in the 8-2.5 A resolution range and 
4084 experimental NMR restraints (see Table 1). (Note, as the tetra- 
mer is completely symmetric in solution, the latter corresponds to 
1021 independent observables.) Refinements were performed using 
the program X-PLOR with a simulated annealing protocol [22], in- 
corporating coupling constant [23] and carbon chemical shift [24] re- 
straints in addition to the usual X-ray structure factor restraints and 
NMR-derived interproton distance and torsion angle restraints. The 
The model of the human ~53 tetramerization domain (Fig. 
1) consists of four crystallographically independent subunits, 
designated A-D as in the NMR model [16], and 80 water 
molecules. The electron density corresponding to monomers 
B and D is very well defined. Several residues of monomer A 
and C, either strained by crystal contacts or exposed to sol- 
vent channels, are partially disordered. The homotetramer has 
Table 1 
Structural statisticsa 
Structural statistics Final model X-rayMMR SA refinement of the final model 
X-ray/NMR X-ray 
X-ray restraints 
R factor (4722/4338)b 
&, (384) 
NMR-derived restraints (4084) 
rmsd from: 
NOE-derived distance restraints (A) (3520) 
Dihedral angle restraints (“) (224) 
3Ju~c, coupling constants (Hz) (112) 
Chemical shifts (ppm) 
13C, (116) 
1scp (112) 
Deviation! from idealized covalent geometry 
Bonds (A) (2260) 
Angles (“) (3836) 
Impropers (“) (1128) 
% residues in the most favoured Ramachandran plot areas 
Bad contacts/100 residues 
0.207 0.205 0.200 
_ 0.297 0.301 
0.075 [14] 0.077 [19] 0.173 [86] 
3.25 [22] 2.79 [19] 10.91 [41] 
1.49 [48] 1.47 [48] 1.74 [60] 
0.74 0.71 0.80 
















aThe number of terms for the complete tetramer for various restra_ints is given in parentheses. 
bThe first number indicates the total number of reflections (8-2.5 A resolution range) used for the final refinement; the second number indicates 
that used for the Rb refinement. 
“The total number of independent experimental NMR restraints is 1021 due to the symmetric nature of the tetramer. The force constants for the 
various terms in the target function are as follows: 15 kcal mol-’ A-’ and 100 kcal mol-l rad-2 for the square-well interproton distance and 
torsion angle restraints terms, respectively; 0.5 kcal mol-’ HZ-~, 0.5 kcal mol-l ppm -‘, 25 kcal mol-l Ae2, 1000 kcal mol-’ Ae2, 500 kcal mol-’ 
rade2, and 500_ kcal mol-’ rad-’ for the harmonic coupling constant, chemical shift, NCS, bond, angle, and improper torsion terms, respectively; 
4 kcal mol-’ Am4 for the quartic van der Waals repulsion term, with the hard sphere van der Waals radii set to 0.8 times the standard van der 
Waals radii used in the PARAM19/PARAM20 CHAl$MM parameters; w, = 1.25 X 105. The number of violations of interproton distance, torsion 
angle, and 3Ju~a coupling constant greater than 0.5 A, 5”, and 1 Hz, respectively, is indicated in square brackets. 
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Fig. 2. Helical wheel representation of an a-helix formed by resi- 
dues 335-353 of human ~53. Residues involved in the helix-helix hy- 
drophobic interactions between subunits of the tetramerization do- 
main are boxed. Residues involved in the interactions between 
monomers AC, AB, or AD are marked by : ::, ///, or \\\, respec- 
tively. 
approximate 222 symmetry with deviations of 1.0, 1.9, and 
0.4” from the ideal 2-fold relating subunits A and B, A and 
C, and A and D, respectively. Corresponding rmsd values are 
0.47, 0.42, and 0.52 A for the superposition of C, atoms; 
however, these values are less than 0.3 A for the superposition 
of all the atoms from residues not involved in the crystal 
contacts. This slight asymmetry is caused by the crystal pack- 
ing and does not affect intersubunit interfaces (see also [16]). 
While inclusion of the NMR observations in the refinement 
had negligible effect on the appearance of electron density, the 
resulting model has improved stereochemistry and is compat- 
ible with data from crystal and solution studies. 
Each subunit of the homotetramer comprises a B-strand 
(residues 326333) and a tight turn (Gly-334) followed by 
an a-helix (residues 335-353). The hairpin structure of the 
monomer is maintained by hydrophobic clusters formed by 
Leu-330, Ile-332, Phe-338, and Phe-341 and is further stabil- 
ized by the hydrogen bond formed by the guanidinium group 
of Arg-337 and the main-chain carbonyl oxygen of Arg-333. 
The topology of the tetramer may best be described as a 
dimer of dimers, with the two dimers arranged orthogonally 
to each other (see Fig. 1). Each primary dimer (subunits AC 
and BD) consists of two antiparallel a-helices and an antipar- 
allel two-stranded P-sheet. The interface between the two di- 
mers is formed by the interactions of their a-helices, which 
form a four-helix bundle. The P-sheets are located on the 
opposite side of the tetramer. 
Residues involved in the hydrophobic helix-helix contacts 
are located at positions 2, 3, 6, and 7 of the helical wheel 
representation shown in Fig. 2. Leu-344 (located close to 
the center of the tetramer) seems to be crucial for tetramer 
formation, since this residue is involved in the interhelical 
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interactions between monomers AC, AB, and AD. Mutation 
of Leu-344 to Ala results in the binding of p53 to DNA as a 
dimer [26]. Phe-338 and Phe-341 interact with the hydropho- 
bic side of the P-sheets located outside the helix bundle, pro- 
viding additional stabilization of the AC interface. The pri- 
mary dimer is also stabilized by a salt bridge between the 
carboxylate of Asp-352A and the guanidinium group of the 
partially buried Arg-337C. 
Residues Arg-335, Arg-342, Glu-349, Glu-339, Glu-346, 
and Ala-353, located at positions 1 and 5 of the helical wheel 
(Fig. 2) are exposed to solvent. As shown in Fig. 3, two 
tetramers in the crystal are related by crystallographic sym- 
metry and are held together by the interactions of their anti- 
parallel aligned helices, with Arg-342 and Glu-346 forming 
salt bridges with symmetry-related Glu-346 (#Glu-346) and 
#Arg-342, respectively. These interactions suggest a possible 
mode for additional oligomerization of ~53, which has been 
observed in vitro [27]. In vivo, the exposed polar side of each 
helix of the tetramerization domain presents a possible site of 
~53 interactions with other cellular or viral proteins, reported 
to form complexes with ~53 [28]. This possibility is supported 
by the finding [29] that the mutation of Glu-349 to Asp occurs 
in a number of human tumors. Glu-349 is involved in crystal 
contacts and does not seem to contribute to the stability of 
the tetramerization domain. Glu-349 is probably important 
for either interdomain or intermolecular interactions. On the 
other hand, three other mutations found in human tumors 
within the ordered part of the oligomerization domain (i.e., 
substitution of His for Leu-330, Val for Gly-334, and Cys for 
Arg-337) involve residues that, as described above, are critical 
for maintaining the structure of the monomer and are also 
important for stabilizing the primary dimer. 
The overall structure agrees very well with published crys- 
tallographic [17] and solution [16] models. The rmsd values 
for the C, atoms of residues 325-355 when the entire tetra- 
merit model was superimposed on the NMR structure [16] or 
the tetragonal crystal structure [17] were 0.73 and 0.48 A, 
respectively. The differences in conformations are observed 
only for residues located on the surface of the tetramer. Water 
molecules identified in the NMR structure [16] are well de- 
fined in the electron density near the main-chain amide groups 
of Arg-333 in monomers A and B. The conformation of Tyr- 
327 in each monomer is different from that in reported struc- 
tures [ 16,171 and, therefore, intermonomer hydrogen bond 
formation with Arg-333 as described for the tetragonal form 
of crystal structure [17] is not possible. Also, a hydrogen bond 
involving Lys-351A and the main-chain carbonyl oxygen of 
Glu-343B [16] is not observed. Thus, the interface between the 
two primary dimers is entirely hydrophobic and should be 
potentially disruptable by small molecule compounds. 
The fact that none of the residues from this interface have 
been found mutated in tumors supports the hypothesis that 
the function of the w-t allele is abrogated in a dominant 
negative fashion by formation of inactive heterotetramers 
composed of w-t and mutated ~53 monomers. This effect 
may be significantly reduced by inhibitors of tetramerization. 
c 
Fig, 1. (Above) Tetramerization domain of ~53 protein. Subunits A, B, C, and D are colored red, green, yellow, and purple, respectively. 
t 
Fig. 3. (Below) Crystal contacts formed by two tetramers in the trigonal crystal lattice. 
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The biological data [4,8] and the location of tumor-derived 
mutations (vide supra) indicate that inducing the dissociation 
to monomers would result in the loss of p53 tumor suppressor 
activity. Therefore, effective drugs should selectively prevent 
the association of the two principal dimers, since the transac- 
tivating function of p53 is retained by its dimeric form [4]. In 
cells expressing one w-t ~53 allele such an approach may 
generate a sufficient number of w-t homodimers to partially 
restore p53 function. 
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